文章：

肝细胞癌当前与前瞻性辅助治疗策略

The Current and Prospective Adjuvant Therapies for Hepatocellular Carcinoma

原文发布日期：6 April 2024

DOI: 10.3390/cancers16071422

类型: Article

开放获取: 是

英文摘要：

Hepatocellular carcinoma (HCC) stands as the most prevalent form of primary liver cancer and is highly invasive and easily recurs. For HCC, chemotherapy shows limited effect. The gold standard for HCC treatment includes curative surgical resection or liver transplantation. However, the recurrence rate at 5 years after liver resection is estimated at approximately 70% and even at 5 years after liver transplantation, it is 20%. Therefore, improving survival outcomes after curative surgical resection of liver cancer is crucial. This review highlights the importance of identifying risk factors for HCC recurrence following radical surgical resection and adjuvant therapy options that may reduce the recurrence risk and improve overall survival, including local adjuvant therapy (e.g., transcatheter arterial chemoembolization and radiotherapy), adjuvant systemic therapy (e.g., small molecule targeted therapy and immunotherapy), and other adjuvant therapies (e.g., chemotherapy). However, further research is needed to refine the use of these therapies and optimize their effectiveness in preventing HCC recurrence.

摘要翻译： 

肝细胞癌（HCC）是最常见的原发性肝癌类型，具有高度侵袭性且易复发。对于HCC，化疗效果有限。HCC治疗的金标准包括根治性手术切除或肝移植。然而，肝切除术后5年复发率估计约为70%，即使在肝移植术后5年，复发率也达到20%。因此，提高肝癌根治性手术切除后的生存结局至关重要。本综述强调了识别根治性手术切除后HCC复发风险因素的重要性，以及可能降低复发风险并提高总生存期的辅助治疗选择，包括局部辅助治疗（如经导管动脉化疗栓塞和放疗）、辅助全身治疗（如小分子靶向治疗和免疫治疗）以及其他辅助治疗（如化疗）。然而，仍需进一步研究以完善这些疗法的应用，并优化其在预防HCC复发方面的效果。

原文链接：

The Current and Prospective Adjuvant Therapies for Hepatocellular Carcinoma